** MiRXES Holding 2629.HK climbs to HK$31.95 on HK debut, up 37.1% from offer price of HK$23.30
** Stock last up 31.8%, outpacing Hang Seng Index's .HSI 0.5% gain and Hang Seng Biotech index's .HSHKBIO 2.3% jump
** Singapore-headquartered micro ribonucleic acid (miRNA) tech co, which specialises in early cancer detection and precision medicine, sells 46.6 mln shares in global offering, raising HK$1.09 bln ($139.2 mln) for R&D, manufacturing, commercialisation of core product
** Jiangsu Hengrui Pharmaceuticals 1276.HK jumps to HK$60.5 on HK debut, up 37.3% from offer price of HK$44.05
** Chinese oncology drug developer sells 224.52 mln H-shares, raising HK$9.89 bln ($1.26 bln) for R&D, constructing production facilities
** Hengrui's Shanghai stock 600276.SS slips 1.6%
($1 = KH$7.8302)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。